CoChat

Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide

Malm-Erjefält, Monika, Ekblom, Marianne, Vouis, Jan, Zdravkovic, Milan, Lennernäs, Hans · 2015 · Molecular Pharmaceutics

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Like other GLP-1 receptor agonists used for treatment of type 2 diabetes, liraglutide delays gastric emptying. In this clinical absorption study, the primary objective was to investigate the effect of liraglutide (at steady state) on the rate and/or extent of gastrointestinal (GI) absorption of concomitantly orally taken drugs from three classes of the Biopharmaceutics Classification System (BCS). To provide a general prediction on liraglutide drug-drug absorption interaction, single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at steady state of liraglutide 1.8 mg, or placebo, in a two-period crossover design. With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h) and did not meet the criterion for bioequivalence for Cmax (reduced Cmax by 27-38%); griseofulvin had similar tmax and 37% increased Cmax. Although the prespecified bioequivalence criterion was not met by all drugs, the overall plasma exposure (AUC) of griseofulvin, atorvastatin, lisinopril, and digoxin only exhibited minor changes and was not considered to be of clinical relevance.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.molpharmaceut.5b00278

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 36

Metadata

Authors
Malm-Erjefält, M., Ekblom, M., Vouis, J., Zdravkovic, M., & Lennernäs, H.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • IQVIA (United States) (US)
  • Uppsala University (SE)
Corresponding author
Malm-Erjefält, Monika
Venue
Molecular Pharmaceutics
Published
2015-10-12
Volume
12
Issue
11
Pages
4166-4173
ISSN
  • 1543-8384 (ISSN-L)
  • 1543-8392
OpenAlex
W2403796176
Cited by
36
References
25
Citations by year
2026: 3 · 2025: 9 · 2024: 7 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 1 · 2017: 1 · 2015: 1
FWCI
0.55
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Pharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, gastrointestinal drug absorption, drug-drug interactions, Biopharmaceutics Classification System, GLP-1 receptor agonists, gastric emptying, atorvastatin, griseofulvin, lisinopril, digoxin, bioequivalence, pharmacokinetics, type 2 diabetes
MeSH terms
Atorvastatin, Liraglutide, Administration, Oral, Adolescent, Adult, Antifungal Agents, Antihypertensive Agents, Biopharmaceutics, Cardiotonic Agents, Computer Simulation, Digoxin, Double-Blind Method, Drug Interactions, Female, Gastric Emptying, Griseofulvin, Humans, Hypoglycemic Agents, Male, Middle Aged, Therapeutic Equivalency, Tissue Distribution, Lisinopril, Cross-Over Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult, Gastrointestinal Absorption

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. https://app.cochat.ai/papers/10.1021/acs.molpharmaceut.5b00278
The paper
Malm-Erjefält, M., Ekblom, M., Vouis, J., Zdravkovic, M., & Lennernäs, H. (2015). Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5b00278

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.